Skip to content

Newborns of Obese Mothers

Impact of Maternal Obesity on Fetal Development and Perinatal Events. Analysis of the Determinants of Fetal Growth.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02681588
Acronym
MOBENN
Enrollment
496
Registered
2016-02-12
Start date
2010-07-31
Completion date
2013-10-31
Last updated
2016-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

diabetes, obesity, skinfold, newborn

Brief summary

This was a prospective bi-centric study, exposed-unexposed. In an effort to better understand the potential independent effect of maternal obesity on fetal growth, investigators designed a prospective study, comparing fetal growth between normal weight (18.5 ≤ BMI \< 25 kg/m2) or obese pregnant women (BMI ≥ 30 kg/m2), while maternal diabetes and hyperglycaemia was screened and treated throughout pregnancy.

Detailed description

The study population concerned obese pregnant women (BMI ≥ 30 kg / m² before pregnancy) and their newborn and normal weight pregnant women (18.5 ≤IMC \<25 kg/m²) and their newborn as control. Inclusion criteria were body mass index (BMI) ≥ 30 kg/m2 or 18.5 ≤ BMI \< 25 kg/m2, 18 ≤ age ≤ 40 years, singleton pregnancy. Exclusion criteria were: 25 ≤ BMI \<30 kg/m2, age \< 18 or \> 40 years, multiple pregnancy, first consultation after 18 WG, pregestational diabetes, obesity due to genetic disorder or secondary to intracranial tumor or radiotherapy, bariatric surgery, chronic diseases other than the obesity, inability to converse in French language. The matching criteria for controls were: age ± 5 years, primigravida or multigravida, duration of gestation ± 4 weeks. The main objective of this project was to assess the independent effect of maternal obesity: * on the weight and adipose tissue of newborn * on the function of adipose tissue (production of leptin and adiponectin) * on fetal growth factors (C-peptide, IGF-1) * on carbohydrate metabolism of the newborn. Two maternities were involved in the study: Pitié Salpêtrière and Armand Trousseau, in Paris, France. This research was conducted over a 3 years period. The duration of participation of each woman corresponded to the duration of pregnancy care and duration of care for the newborn immediately after birth, usually the length of stay in the maternity. The only differences compared to the usual care included: * Additional oral glucose tolerance test at 32 weeks of gestation; * Determination of fasting blood glucose during late pregnancy * Maternal blood samples on arrival at the delivery room * Drawing blood from the umbilical cord after section; * Skinfold measurement of the newborn within 72 hours of life.

Interventions

PROCEDUREObstetric management

Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. \- BMI ≥30 kg / m² or between 18.50 and 24.99 kg / m². 2. \- Pregnant woman coming to the centre before 18 weeks of gestation. 3. \- Age ≥ 18 and ≤ 40 years 4. \- Single Pregnancy 5. \- No constitutional or progressive disease other than obesity: inflammatory disease, epilepsy, pathology psychiatric, tumor... 6. \- Informed written consent.

Exclusion criteria

1. \- Pregnant woman coming to the center after 18 weeks of gestation, BMI \<18.5 kg / m² or between 25 and 29.99 Kg / m². 2. \- Age \<18 or\> 40 years 3. \- Multiple pregnancy 4. \- Presence of a constitutional disease or progressive disease other than obesity. 5. \- Patients who underwent obesity surgery type bypass or gastroplasty 6. \- Obesity secondary to genetic disorder, intracranial lesions or pituitary radiotherapy 7. \- not stabilized endocrine pathology. 8. \- pregestational diabetes 9. \- No affiliation to a social security scheme

Design outcomes

Primary

MeasureTime frame
ponderal index measured by a balanceat birth
skinfold's measure measured by a special clampat birth
birthweightat birth

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026